TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04060940

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotion Regulation Therapy: 8-session version
Description: Emotion Regulation Therapy will be administered over 8 individual sessions on a weekly basis, resulting in a total required time commitment of 9 hours over the course of 8 weeks. The initial stage of treatment focuses on psychoeducation about anxiety and depression, individual patterns of these behaviors, emotions in recent situations, and self-monitoring of worry, anxiety, and depression. The sessions focus on the development of skills that help regulate one's emotional experience (i.e., recognizing emotions when they are happening, identifying the meaning of a given emotion experience, and soothing oneself in the context of negative emotional experiences). Following the development of these skills, sessions focus on the application of somatic awareness and emotion regulation skills while imagining emotionally evocative themes. The remaining sessions focus on terminating therapy, relapse prevention, and future goals.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotion Regulation Therapy: 16-session version
Description: Emotion Regulation Therapy will be administered over 16 individual sessions on a weekly basis, resulting in a total required time commitment of 18 hours over the course of 16 weeks. The initial stage of treatment focuses on psychoeducation about anxiety and depression, individual patterns of these behaviors, emotions in recent situations, and self-monitoring of worry, anxiety, and depression. The sessions focus on the development of skills that help regulate one's emotional experience (i.e., recognizing emotions when they are happening, identifying the meaning of a given emotion experience, and soothing oneself in the context of negative emotional experiences). Following the development of these skills, sessions focus on the application of somatic awareness and emotion regulation skills while imagining emotionally evocative themes. The remaining sessions focus on terminating therapy, relapse prevention, and future goals.
Study: NCT00725426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosutinib
Study: NCT02207829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Umeclidinium
Description: Umeclidinium 62.5 mcg once daily in the morning via nDPI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Umeclidinium matching placebo
Description: Umeclidinium matching placebo once daily in the morning via nDPI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium
Description: Tiotropium 18 mcg once daily in the morning via HANDIHALER inhaler

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium matching placebo
Description: Tiotropium matching placebo once daily in the morning via HANDIHALER inhaler
Study: NCT02952235

Intervention type: OTHER
Group type: OTHER
Intervention: SPF100+
Description: Sun protection
Study: NCT00215943

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: zoledronic acid
Description: Patients were randomized to receive zoledronic acid I.V. on either Day 1 or 15 of each cycle. This schedule continued monthly as long as the patient remained on study. The dose was calculated based on the patients' monthly creatinine clearance.
Study: NCT01461590

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Whole blood
Description: 30mls/kg transfused over fours hours

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole blood
Description: 30mls/kg transfused over fours hours

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Whole blood
Description: 20mls/kg transfused over four hours

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole blood
Description: 20mls/kg transfused over four hours
Study: NCT01094275

Intervention type: DRUG
Intervention: Clopidogrel 75mg, Omeprazole 20mg
Description: Clopidogrel and or Omeprazole as applicable

Intervention type: DRUG
Intervention: Clopidogrel 75mg, Omeprazole 20mg
Description: Clopidogrel and or Omeprazole as applicable

Intervention type: DRUG
Intervention: Clopidogrel 75mg, Omeprazole 20mg
Description: Clopidogrel and or Omeprazole as applicable

Intervention type: DRUG
Intervention: Clopidogrel 75mg, Omeprazole 20mg
Description: Clopidogrel and or Omeprazole as applicable
Study: NCT04589585

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DiVeRt
Description: DiVeRt - Vascular Reconstruction Device and Delivery System
Study: NCT00965848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doripenem
Description: Doripenem 500 mg will be administered as 1 or 4 hours intravenous infusion, after every 8 hours up to maximum of 14 days.
Study: NCT00965848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doripenem
Description: Doripenem 500 mg will be administered as 1 or 4 hours intravenous infusion, after every 8 hours up to maximum of 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doripenem
Description: Doripenem 500 mg will be administered as 1 or 4 hours intravenous infusion, after every 8 hours up to maximum of 14 days.
Study: NCT00215943

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone
Description: As outlined in VAD Treatment arm and Thalidomide and Dexamethasone Treatment arm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: thalidomide
Description: As outlined in Thalidomide and Dexamethasone Treatment arm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vincristine
Description: As outlined in VAD Treatment Arm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adriamycin
Description: As outlined in VAD Treatment arm
Study: NCT03332589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E6201
Description: E6201 formulated in cyclodextrin for IV administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E6201 plus dabrafenib
Description: E6201 formulated in cyclodextrin for IV administration. Dabrafenib capsules for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E6201 plus dabrafenib
Description: E6201 formulated in cyclodextrin for IV administration. Dabrafenib capsules for oral administration.
Study: NCT03624023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TWB-103
Description: TWB-103 will be applied to the target ulcer wound once a week by the investigator, starting from Day 1, until wound closure is confirmed or up to 12 weekly applications
Study: NCT03990376

Intervention type: OTHER
Group type: OTHER
Intervention: Radioisotope I-131-labeled albumin
Description: 1 mL of radioisotope I-131-labeled albumin x 2
Study: NCT01563445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: activated recombinant human factor VII
Description: Subjects will be randomised to receive a single intravenous dose of either 5, 20, 40 and 80 mcg/kg body weight. Administered within the first 4 hours after the insult

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Subjects will be randomised to receive a single intravenous dose. Administered within the first 4 hours after the insult
Study: NCT03190941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Days -7 and -6: Cyclophosphamide 60 mg/kg/day x 2 days IV in 250 mL D5W infused simultaneously with mesna 15 mg/kg/day over 1 hour x 2 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Days -7 and -6: Cyclophosphamide 60 mg/kg/day x 2 days IV in 250 mL D5W infused simultaneously with mesna 15 mg/kg/day over 1 hour x 2 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Days -7 to -3: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Days -7 to -3: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-KRAS G12V mTCR PBL
Description: Day 0: Cells will be infused intravenously on the Patient Care Unit over 20-30 minutes (2-4 days after the last dose of fludarabine).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-KRAS G12V mTCR PBL
Description: Day 0: Cells will be infused intravenously on the Patient Care Unit over 20-30 minutes (2-4 days after the last dose of fludarabine).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 3 days (maximum 9 doses).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 3 days (maximum 9 doses).
Study: NCT02014298

Intervention type: RADIATION
Group type: OTHER
Intervention: non-ablative fractional laser
Description: 3 treatments with 4-6 weeks interval

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control
Description: observation, comparison to laser-treated area
Study: NCT02333747

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: the Hans electronic acupuncture apparatus
Description: TEAS was performed with a dense-disperse frequency of 2/10 Hz and an intensity of 6-9 mA for 30 min using the Hans electronic acupuncture apparatus (HANS-100A, Nanjing Jisheng Medical Technology Company, Nanjing, China).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: the Hans electronic acupuncture apparatus
Description: TEAS was performed with a dense-disperse frequency of 2/10 Hz and an intensity of 6-9 mA for 30 min using the Hans electronic acupuncture apparatus (HANS-100A, Nanjing Jisheng Medical Technology Company, Nanjing, China).
Study: NCT04034095

Intervention type: DRUG
Intervention: Androgen-deprivation Therapy (ADT)
Description: Participants enrolled in this study will continue to receive ADT (example- Leuprorelin, Goserelin and Degarelix) alone or in combination with other therapies in routine clinical practice as directed by their treating physician. No intervention will be administered as a part of this study.

Intervention type: DRUG
Intervention: Androgen-deprivation Therapy (ADT)
Description: Participants enrolled in this study will continue to receive ADT (example- Leuprorelin, Goserelin and Degarelix) alone or in combination with other therapies in routine clinical practice as directed by their treating physician. No intervention will be administered as a part of this study.

Intervention type: DRUG
Intervention: Bicalutamide
Description: Participants enrolled in this study will continue to receive bicalutamide along with ADT in routine clinical practice as directed by their treating physician. No intervention will be administered as a part of this study.

Intervention type: DRUG
Intervention: Abiraterone
Description: Participants enrolled in this study will continue to receive abiraterone in combination with prednisolone along with ADT in routine clinical practice as directed by their treating physician. No intervention will be administered as a part of this study.

Intervention type: DRUG
Intervention: Prednisolone
Description: Participants enrolled in this study will continue to receive prednisolone in combination with abiraterone along with ADT in routine clinical practice as directed by their treating physician. No intervention will be administered as a part of this study.

Intervention type: DRUG
Intervention: Docetaxel
Description: Participants enrolled in this study will continue to receive docetaxel along with ADT in routine clinical practice as directed by their treating physician. No intervention will be administered as a part of this study.

Intervention type: DRUG
Intervention: Enzalutamide
Description: Participants enrolled in this study will continue to receive enzalutamide along with ADT in routine clinical practice as directed by their treating physician. No intervention will be administered as a part of this study.

Intervention type: DRUG
Intervention: Apalutamide
Description: Participants enrolled in this study will continue to receive apalutamide along with ADT in routine clinical practice as directed by their treating physician. No intervention will be administered as a part of this study.
Study: NCT02599077

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dienogest
Description: patients assigned to this treatment receive 2 milligrams per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levonorgestrel
Description: patients assigned to this treatment receive (0.10 mg levonorgestrel + ethinyl estradiol - 0.02 milligrams daily)
Study: NCT05582447

Intervention type: OTHER
Intervention: ektacytometry of red blood cells
Description: Evaluate red blood cell membrane mechanical characteristics by osmotic gradient ektacytometry

Intervention type: OTHER
Intervention: ektacytometry of red blood cells
Description: Evaluate red blood cell membrane mechanical characteristics by osmotic gradient ektacytometry
Study: NCT03827460

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Abstinence from alcohol
Description: Participants will undergo a laboratory alcohol infusion session that terminates 2 weeks of monitored abstinence from alcohol

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Abstinence from alcohol
Description: Participants will undergo a laboratory alcohol infusion session that terminates 2 weeks of monitored abstinence from alcohol

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual drinking
Description: Participants will undergo a laboratory alcohol infusion session during a period of usual drinking behavior

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual drinking
Description: Participants will undergo a laboratory alcohol infusion session during a period of usual drinking behavior

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Alcohol
Description: During the laboratory alcohol infusion sessions, alcohol is infused through an indwelling catheter.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Alcohol
Description: During the laboratory alcohol infusion sessions, alcohol is infused through an indwelling catheter.
Study: NCT03706209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP1032
Description: hard gelatin capsules containing 50mg MP1032 as active ingredient

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP1032
Description: hard gelatin capsules containing 50mg MP1032 as active ingredient

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: hard gelatin capsules containing no active ingredient

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: hard gelatin capsules containing no active ingredient
Study: NCT04188678

Intervention type: OTHER
Group type: OTHER
Intervention: Bone Marrow Transplant (BMT)
Description: Bone marrow transplantation will be conducted according to the investigators' institution's standard of care, or else according to research protocol (if applicable).Study visits that include the performance of assessments will occur prior to the start of conditioning chemotherapy and at 1 month and 6 months post-BMT. All dates are +/- 7 days. The initial study visit will take place during standard of care pre-transplant evaluations, which typically span 3-4 days. The post-BMT visits will take place before or after regularly-scheduled BMT follow up.
Study: NCT04758611

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: eShunt™ Implant
Description: The eShunt™ Implant is designed to drain excess cerebrospinal fluid (CSF) from the intracranial subarachnoid space (SAS) into the venous system as a minimally invasive treatment for communicating hydrocephalus.
Study: NCT03596086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADV/HSV-tk (gene therapy)
Description: The investigational adenovirus gene therapy injected at tumor site followed by valacyclovir, radiotherapy, and chemotherapy
Study: NCT03646344

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heme Arginate 25 MG/ML
Description: IMP - to be administered at a dose of 3mg/kg to a maximum dose of 250mg over 30 mins. Participants will receive intervention twice during the trial, one on Day 0 (day of transplantation) and then again on D1 (20-28 hours after dose 1).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Sodium-chloride
Description: Placebo - 100ml of 0.9% Sodium Chloride will be given over 30 mins. Participants will receive intervention twice during the trial, one on Day 0 (day of transplantation) and then again on D1 (20-28 hours after dose 1).
Study: NCT03658720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200 mg Ibuprofen acid orodispersible tablet
Description: orodispersible tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200 mg Ibuprofen acid orodispersible tablet
Description: orodispersible tablet
Study: NCT00435123

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional Supplement ProStat 64 twice a day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo supplement
Description: Patients randomly assigned to Placebo for the first 3 months will receive open label Prostat for the last 3 months
Study: NCT04018872

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Oral administration of itraconazole twice daily from completion of neoadjuvant chemoradiation until esophagectomy.
Study: NCT00677339

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-arginine
Description: L-arginine 6g orally daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-arginine
Description: L-arginine 6g orally daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: Cholecalciferol 50000 IU once monthly orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: Cholecalciferol 50000 IU once monthly orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo L-arginine
Description: placebo L-arginine once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo L-arginine
Description: placebo L-arginine once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Vitamin D
Description: placebo vitamin D orally once monthly

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Vitamin D
Description: placebo vitamin D orally once monthly
Study: NCT04127032

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PSP Wellbeing Course
Description: A tailored ICBT intervention will be delivered to public safety personnel who report symptoms of depression, anxiety, or posttraumatic stress. Clients will choose whether they prefer weekly therapist support, twice-weekly support, or monitored optional support. The intervention is designed to be completed in 8 weeks, but clients will be able to extend their access to therapist support by an additional 8 weeks (i.e., up to 16 weeks in total).
Study: NCT03144726

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy
Description: Negative pressure wound therapy is a commonly utilized tool in the hospital setting and will be applied to amputations in our study to determine the effect on surgical site infections

Intervention type: OTHER
Group type: OTHER
Intervention: Standard dressing
Description: A standard dressing will be applied to the amputations in this arm of the study
Study: NCT04275648

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: AsthmaTuner exercise field test
Description: AsthmaTuner consist of a a bluetooth spirometer and smartphone app with protocol for measuring lung function (FEV1) and perform 8 min exercise challenge test and a healthcare web interface.
Study: NCT02835014

Intervention type: BEHAVIORAL
Intervention: Mental Health Symptoms
Description: Adolescents with T1DM will be asked to complete PHQ9 (depression screening), SCARED (anxiety screening) and UCLA PTSD (trauma screening)

Intervention type: BEHAVIORAL
Intervention: Self-efficacy regarding self-care and diabetes management
Description: Adolescents with T1DM will be asked to complete the SEDM to asses self-efficacy for diabetes management

Intervention type: BEHAVIORAL
Intervention: Parenting Styles
Description: Parents of adolescents with T1DM will be asked to complete the PSDQ to asses parenting style
Study: NCT04261816

Intervention type: PROCEDURE
Intervention: extubation in the operating room
Description: Patients who underwent liver transplantation early extubation in the operating room immediately following liver transplantation

Intervention type: PROCEDURE
Intervention: extubation in the ICU
Description: Patients who underwent liver transplantation extubation in the ICU following liver transplantation
Study: NCT02787616

Intervention type: GENETIC
Intervention: buccal swab
Description: cheek swab for DNA sampling

Intervention type: GENETIC
Intervention: buccal swab
Description: cheek swab for DNA sampling
Study: NCT02733497

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sympathectomy
Description: Resection of ganglia at T3 level

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sympathicotomy
Description: Cutting of symptahetic chain at T3 level without ganglia excision
Study: NCT02946294

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 0.25% with epinephrine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 0.25% with epinephrine
Study: NCT03313596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADV-Tk
Description: The first ADV-TK dose was administered during the operation; 1.0×10(12) viral particles of ADV-TK in 100 mL of 0.9% saline were injected into peritoneum tissues around the liver. The second and third ADV-TK dose was administered 60 days and 90 days after LT; 1.0×10(12) viral particles of ADV-TK in 100 mL of 0.9% saline were injected into the celiac artery (60 mL) and the superior mesenteric artery (40 mL) via femoral-artery puncture.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LT
Description: Orthotopic LT and subsequent immunosuppression therapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LT
Description: Orthotopic LT and subsequent immunosuppression therapy
Study: NCT01919385

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Predictive Low Glucose Minimizer
Description: This study is a non-randomized feasibility study enrolling type 1 diabetics who are currently using an insulin pump. Participating Investigators will closely monitor the study subject in a clinical research center environment for approximately 30 hours, while controller algorithm determined insulin doses are delivered by an insulin pump, and utilizing continuous glucose monitoring results.
Study: NCT04547959

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cervical interbody cage C-CURVE
Description: ACDF: Anterior Cervical Discectomy and Fusion with a C-CURVE cage